Skip to content Skip to footer
Subscribe Now
PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
VIEWPOINTS

PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting

Shots: Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonist Richard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumab The interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumors Smriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 2022

Read more

PharmaShots Interview In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
VIEWPOINTS

PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)

Shots: Arnold spoke about Cecelia Health’s collaboration with the UBMD Paediatrics for a clinical study to improve health outcomes for children and adolescents living with T1D Arnold also gave his views on how telehealth options can support the unmet needs of patients with T1D The interview provides a gist of the challenges of living with…
June 20, 2022

Read more

PharmaShots Interview In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
VIEWPOINTS

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

Shots: Leonard spoke about the newly developed radiotherapy-activated nanoparticle and other cancer therapies developing in Nanobiotix’s pipeline James shared his views on the data presented at the 2022 Annual Meeting of the American Association of Cancer Research The interview provides a core understanding of Nanobiotix’s outlook to expand the utility of nanoparticles in cancer treatment…
June 15, 2022

Read more

PharmaShots Interview In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs
VIEWPOINTS

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

Shots: Ian spoke about the study design of the clinical trials of its lead iNKT agonists He also emphasized the advancement of novel immunotherapies through new collaborations  The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatment Smriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…
June 8, 2022

Read more

PharmaShots Interview In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
VIEWPOINTS

PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza

Shots: Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza Smriti:…
June 6, 2022

Read more

Insights+ Key Biosimilars Events of May 2022
INSIGHTS+

Insights+ Key Biosimilars Events of May 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, JSR Life Sciences launches Similis Bio business…
June 2, 2022

Read more

PharmaShots Interview In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
VIEWPOINTS

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space

Shots: Thierry spoke about the IND clearance of its lead candidate in hypoparathyroidism and the company’s clinical trial plans for rare endocrine and related diseases Thierry also communicated about the closing of funding Series B equity financing round The interview gives a deeper understanding of Hypoparathyroidism and its treatment options Smriti: What did this Investigational…
June 1, 2022

Read more

Load more